Plain-English translation of NCT07488897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called that you spray into your nose to see if it can help people with asthma. The study happens in two parts: first, researchers will give healthy people and people with asthma increasing doses of the medication to make sure it's safe and well-tolerated. Then, in the second part, people with asthma will receive the medication and be intentionally exposed to a common cold virus to see if the treatment helps protect their airways.
Many people with asthma find that their symptoms get much worse when they catch a cold or other respiratory infection, and current treatments don't always prevent this. Researchers are testing this medication to see if it can reduce airway inflammation and help prevent asthma flare-ups triggered by viral infections.
You likely qualify if…
You likely don't qualify if…
If you join, you'll either receive the new nasal spray or a placebo (inactive spray) at clinic visits over several weeks, with your lung function and symptoms monitored closely. In the second part of the study, if you have asthma and qualify, you'll receive the medication and then be deliberately exposed to a common cold virus in a controlled setting so researchers can see how well the treatment protects your airways. Throughout the trial, you'll have breathing tests, blood tests, and regular check-ins with the research team.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United Kingdom
Phase
Safety & dosing / Early efficacy
Sponsor
RIGImmune Inc.
Collaborators
Virtus Respiratory Research, Medicines Evaluation Unit Ltd
Enrollment target
~82 participants
Started
February 2026
Primary completion
February 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.